secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017924
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences Q1 net loss $19M; cash $73M; herpesvirus candidate ABI-5366 advancing to IND
--------------------------------------------------------------------------------

- Net loss of $19.0M ($0.37 per share) vs $23.1M ($0.48) in Q1 2022; R&D expenses $14.5M down from $17.2M.
- Cash, cash equivalents and marketable securities $73.0M as of March 31, 2023, projected to fund ops into Q3 2024.
- Nominated first herpesvirus candidate ABI-5366; plans to enter clinic first half 2024; expects additional candidate nomination in 2023.
- Evaluating partnering options for core HBV inhibitor portfolio to focus on expanded virology programs.
- Multiple abstracts accepted for presentation at EASL 2023 in June for HBV/HDV entry inhibitor and core inhibitor data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023017924/0000950170-23-017924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023017924/asmb-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer